Peptides for Menopause: What They Can Help With, and What They Cannot

Estradiol falls and becomes erratic, progesterone drops as ovulation becomes infrequent, and follicle-stimulating hormone rises. Those changes drive vasomotor symptoms, genitourinary changes and accelerated bone loss, and they are what hormone therapy addresses. No peptide on this page touches any of them. Growth hormone secretion, and the deep sleep tied to it, declines across midlife on a separate, slower curve; that is the axis the growth-hormone secretagogues act on.

Night sweats wake people directly. Loss of progesterone removes a mildly sedating hormone. Slow-wave sleep declines with age alongside growth hormone secretion, a relationship described in a 2000 JAMA analysis of sleep and hormone levels across adult life. Sleep apnea becomes more common after menopause and presents as insomnia rather than snoring. Which of those is driving the waking determines whether a peptide is even the right category of answer.

Average weight gain through the transition is modest, but fat shifts toward the abdomen, lean mass declines, resting energy expenditure falls and insulin sensitivity worsens. Any weight-loss intervention at this stage has to protect muscle and bone rather than just remove weight.

The dermatology literature describes a marked drop in dermal collagen in the years after the final period. Hair shedding in this decade is at least as often thyroid disease, iron deficiency or female-pattern hair loss as an estrogen effect. Low desire is rarely one thing: dryness and pain make sex unappealing before desire is in question, poor sleep and low mood remove appetite for it, and a smaller central component is what the melanocortin peptides act on. Mood symptoms overlap almost completely with thyroid disease, iron deficiency and untreated sleep disruption, which is why screening comes before any prescription.

DSIP, delta sleep-inducing peptide, is a nonapeptide characterized in a 1977 paper in Proceedings of the National Academy of Sciences. It is not a sedative: the research describes effects on sleep architecture and stress-response signaling rather than time to fall asleep. The human evidence is old, small and mixed: a 1981 Lancet report described improved sleep in insomniacs, a 1992 double-blind study in Neuropsychobiology reported inconsistent results, and a 2006 J Neurochem review called it "a still unresolved riddle." There are no modern randomized trials of DSIP.

Directions are 0.25 mL (25 units) subcutaneously Monday through Friday nights at bedtime. It suits light, unrefreshing sleep without an obvious night-sweat trigger. See what DSIP is and peptides for sleep.

SERENITY combines DSIP with Selank and the growth-hormone secretagogue pair CJC-1295 and ipamorelin, on the logic that the menopausal 3am wake is usually a stress-axis event layered on age-related loss of deep sleep. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported prolonged increases in growth hormone and IGF-1 from CJC-1295 in healthy adults, and ipamorelin was characterized in 1998 in the European Journal of Endocrinology as the first selective growth hormone secretagogue. Neither has a sleep trial; what patients describe is most often sleep depth rather than onset.

Directions are the same as DSIP alone, and bloodwork is commonly required because the blend acts on the growth hormone axis. If night sweats are the waker, treat the night sweats; that is the hormone conversation, not this one.

Semaglutide is a GLP-1 receptor agonist with the deepest human evidence of anything here. STEP 1, in the New England Journal of Medicine in 2021, randomized nearly two thousand adults with overweight or obesity to weekly semaglutide or placebo for 68 weeks; STEP 5 in Nature Medicine in 2022 extended follow-up to two years; SELECT in NEJM in 2023 reported cardiovascular outcomes. The STEP program enrolled a majority of women averaging their mid-forties, though no trial selected for menopausal status.

Weight lost on a GLP-1 medication is mostly fat but includes lean mass, a real cost at this stage; resistance training and protein are part of the prescription. Compounded semaglutide shares the active ingredient with the approved products but not the approval, comes in dose-specific vials stepped up by your physician, and commonly requires bloodwork. Contraception is discussed first. See best peptides for weight loss.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. SURMOUNT-1, in NEJM in 2022, randomized over two and a half thousand adults with obesity for 72 weeks; SURMOUNT-5, in NEJM in 2025, compared it directly against semaglutide and reported greater weight loss with tirzepatide; SURMOUNT-OSA, in NEJM in 2024, reported improvement in obstructive sleep apnea, a hidden cause of menopausal sleep disruption.

The compounded preparation comes in dose-specific vials paired with vitamin B12. The same lean-mass and contraception cautions apply, and both GLP-1 medications are excluded by a personal or family history of medullary thyroid carcinoma or MEN 2. Which is chosen, if either, is your physician's decision.

GHK-Cu is a copper-binding tripeptide that occurs naturally in plasma and declines with age. It acts as a copper carrier, and research describes increased synthesis of collagen, elastin and proteoglycans along with modulation of the enzymes that break tissue down. It has the deepest literature of the repair peptides, including human skin work. RADIANCE pairs it with tesamorelin.

A 1988 FEBS Letters paper described GHK-Cu stimulating collagen synthesis in cultured fibroblasts, and reviews in BioMed Research International in 2015 and the International Journal of Molecular Sciences in 2018 summarize the gene-expression work. The human data is topical, including a 2006 Archives of Facial Plastic Surgery study on laser-resurfaced skin; there are no randomized trials of injectable GHK-Cu.

Directions are 0.25 mL (25 units) subcutaneously once daily Monday through Friday. Because it delivers copper, Wilson's disease and high-dose zinc are the specific cautions. See what GHK-Cu is.

RADIANCE puts GHK-Cu and tesamorelin in one vial. Tesamorelin has full randomized trials: the 2007 NEJM trial in HIV-infected adults with abdominal fat accumulation, a 2014 JAMA trial reporting reduced visceral and liver fat in the same population, and a 2012 JCEM study in obese adults with reduced growth hormone secretion. The FDA approved it as Egrifta on 10 November 2010 for excess abdominal fat in HIV-infected adults with lipodystrophy; the label states it is not indicated for weight loss management, that IGF-1 should be monitored, and that active malignancy and pregnancy are contraindications.

RADIANCE suits a skin complaint that sits alongside a shift toward abdominal fat. Directions are 0.25 mL (25 units) subcutaneously once daily Monday through Friday; bloodwork is commonly required. Use outside the HIV indication is an extrapolation.

PT-141, bremelanotide, is a melanocortin receptor agonist acting centrally on desire rather than on blood flow, and the one product here whose active ingredient is FDA approved for a women's-health indication. The FDA approved Vyleesi on 21 June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder; the label states it "is not indicated for the treatment of HSDD in postmenopausal women or in men." Use after menopause is an extrapolation from that evidence.

The two RECONNECT phase 3 trials, in Obstetrics and Gynecology in 2019, randomized over twelve hundred premenopausal women with HSDD and reported improvements in desire and reductions in distress. Nausea is the defining side effect: the label reports it in 40 percent of treated patients, improving for most by the second dose, and records a transient rise in blood pressure after each dose.

Directions are 0.50 mL (50 units) subcutaneously two to four hours before sexual activity, no more than four doses per month. It suits the person whose desire is what has changed and for whom sex is otherwise comfortable; uncontrolled blood pressure rules it out. See peptides for libido.

Selank is a synthetic heptapeptide derived from tuftsin, developed in Russia, and described in that research as modulating GABAergic and serotonergic signaling with anxiolytic effects reported without benzodiazepine-type sedation. The human evidence is Russian, mainly in the Korsakov journal: a 2008 study in generalized anxiety disorder and a 2014 comparison against the benzodiazepine phenazepam. They are small, and none is a menopause study.

Directions are 0.25 mL (25 units) subcutaneously once daily Monday through Friday. It suits mental clutter and a stress response that will not switch off, more than low mood; mood changes through this transition sometimes need psychiatric care rather than a peptide. See what Selank is.

NAD+ is a coenzyme, not a peptide, central to cellular energy metabolism, and a 2012 PLOS ONE study described its decline in human tissue with age. The human outcome data comes almost entirely from oral precursors and is thinner than the marketing suggests: a 2021 Science trial in postmenopausal women with prediabetes reported that ten weeks of nicotinamide mononucleotide increased muscle insulin sensitivity compared with placebo, while a 2018 American Journal of Clinical Nutrition trial in obese men found no change. There are no randomized trials of injected NAD+ for energy.

Directions are 0.83 mL (83 units) subcutaneously three times per week, as a vial or a pre-filled Pen cartridge. It suits flat energy once thyroid, iron and B12 have been checked and found normal. See what NAD+ is.

BPC-157 + TB-500 is the pairing for the tendon and joint aches that cluster around this age. Rat studies in the Journal of Orthopaedic Research in 2003 and 2006 described faster recovery of transected and detached Achilles tendon with BPC-157; TB-500 is a fragment of thymosin beta-4, described in a 2005 Trends in Molecular Medicine review as promoting cell migration and tissue repair; a 2026 study in Joint Diseases and Related Surgery examined the two together in rat Achilles tendon. There are no randomized human trials of BPC-157 or TB-500 for tendon or joint pain.

Directions are 0.25 mL (25 units) subcutaneously Monday through Friday mornings. It suits a specific sore tendon alongside the loading and physiotherapy that have actual trial evidence, and does not substitute for investigating a joint that is swollen, hot or newly stiff.

Semaglutide and tirzepatide are FDA-approved active ingredients; the compounded vials are not approved products. Shortage-based compounding has ended: the FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025. What remains is the ordinary 503A pathway: a state-licensed pharmacy may compound for an identified patient where the prescriber determines and documents that the compounded product differs from the commercial one in a way that matters for that patient; the FDA updated that guidance on 1 April 2026. A separate April 2026 proposal to exclude both from the 503B bulks list concerns outsourcing facilities and is not final.

Bremelanotide was approved as Vyleesi on 21 June 2019 and tesamorelin as Egrifta on 10 November 2010. Because a component of an approved product may be used in 503A compounding, neither depends on the 503A bulks list and neither was ever in Category 2. The "essentially a copy" rule applies instead, and whether a compounded multi-dose vial with physician-set directions is warranted for you is your physician's determination.

The four SERENITY components were placed in Category 2 of the FDA's interim 503A bulk drug substances list in September 2023, the category for substances with identified safety concerns. None is there now: the FDA's safety-risks page, current as of 22 April 2026, lists all four among substances "nominated but withdrawn," and the category list updated 14 May 2026 shows none of them in Category 1, 2 or 3.

DSIP, listed by the FDA as emideltide, was among the twelve peptides removed from Category 2 on 15 April 2026; on 24 July 2026 the Pharmacy Compounding Advisory Committee voted 6 in favor, 7 against, with 1 abstention, and did not recommend adding it to the 503A Bulks List. Selank came off Category 2 in September 2024 after the FDA recorded that the nominator had intended to nominate a different substance. CJC-1295 and ipamorelin were each reviewed by the committee in late 2024 and voted against, then withdrawn; ipamorelin acetate still carries a Category 2 entry under the separate 503B policy for outsourcing facilities, which is not the 503A pathway under which SERENITY is compounded.

A committee vote is a recommendation, not an agency action; the FDA has issued no final determination on any of the four, a "no" vote is not a ban, and all four remain legal to prescribe and dispense.

Injectable GHK-Cu, BPC-157 and TB-500 were all among the twelve peptides removed from Category 2 on 15 April 2026. On 23 July 2026 the advisory committee voted 8 to 6 with one abstention to recommend adding BPC-157 to the 503A Bulks List, and the same for TB-500. GHK-Cu was not on that agenda; the FDA has said the committee will consider it before the end of February 2027. All three await the FDA's final determination.

NAD+ was never in Category 2. Nicotinamide adenine dinucleotide sits in Category 1, "Bulk Drug Substances Under Evaluation," in the list updated 14 May 2026, and under the interim policy the FDA does not intend to act against a compounder using a Category 1 substance while evaluation is pending.

Compounded medications are prepared by a state-licensed pharmacy to an individual prescription; they are not reviewed by the FDA for safety or effectiveness and are never approved as finished products, whatever the status of their ingredient. What a legitimate provider shows you instead is the pharmacy's identity and testing, which for Pepti is on the quality page and in the lab results.

The 2026 WADA Prohibited List prohibits at all times CJC-1295, sermorelin and tesamorelin as growth-hormone-releasing-hormone analogs, ipamorelin as a growth hormone secretagogue, and thymosin beta-4 and its derivatives including TB-500; BPC-157 is named under S0 as a non-approved substance. That covers SERENITY, RADIANCE and the BPC-157 + TB-500 pairing. A tested athlete should check with their sport's anti-doping body and tell the physician.